Last reviewed · How we verify
The treatment of investigator choice — Competitive Intelligence Brief
phase 3
Oncology
Small molecule
Live · refreshed every 30 min
Target snapshot
The treatment of investigator choice (The treatment of investigator choice) — LintonPharm Co.,Ltd.. The treatment of investigator choice works by targeting the underlying cause of the disease.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| The treatment of investigator choice TARGET | The treatment of investigator choice | LintonPharm Co.,Ltd. | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- The treatment of investigator choice CI watch — RSS
- The treatment of investigator choice CI watch — Atom
- The treatment of investigator choice CI watch — JSON
- The treatment of investigator choice alone — RSS
Cite this brief
Drug Landscape (2026). The treatment of investigator choice — Competitive Intelligence Brief. https://druglandscape.com/ci/the-treatment-of-investigator-choice. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab